European venture capital momentum: Constellr and Aerska drive innovation in space tech and RNA biotech

In a strong start to 2026, European venture capital markets are demonstrating vibrant activity across deep tech and biotech sectors. Two headline deals reported on 10 February 2026 illustrate this momentum: Constellr’s €37 million Series A funding round for space data expansion, and Aerska’s €32 million financing to accelerate RNA therapeutic development for central nervous system diseases.

These transactions highlight the growing sophistication of European VC ecosystems and underscore increasing investor appetite for capital-intensive, high-growth potential companies outside traditional tech hubs.

Constellr closes €37M series A funding to boost satellite services

Munich-based Constellr has successfully closed a €37 million Series A funding round, securing capital to bolster its satellite constellation and commercial data services. Positioned at the intersection of earth observation and space tech, Constellr is focused on delivering high-resolution data products and analytics to address challenges across climate, environment, and industrial monitoring.

The funding round—which attracted strategic and institutional investors—marks a significant milestone in European space ventures, where the race to build scalable satellite infrastructure parallels developments in the U.S. and Asia.

Key highlights of the deal include:

1. Growth capital for constellation deployment
2. Enhanced data analytics and commercial service expansion
3. Strengthened position against global competitors in earth observation

This investment signals confidence in Europe’s capacity to nurture space tech leaders capable of competing on a global stage, particularly as demand for geospatial intelligence grows across sectors from agriculture to energy.

Top biotech company Aerska raises €32M to advance RNA Therapeutics

In the biotech sphere, Irish biotech Aerska announced the successful closure of a €32 million funding round aimed at advancing its RNA medicine platform targeting central nervous system (CNS) diseases.

Leveraging cutting-edge RNA technology, Aerska’s therapeutic pipeline focuses on conditions with significant unmet medical need, combining innovative science with a clear clinical vision. The financing will enable:

1. Acceleration of clinical development
2. Expansion of therapeutic targets
3. Strengthened research capabilities

This fundraising event underscores Europe’s growing prominence in biotech innovation—especially in RNA and genetic medicine areas traditionally dominated by U.S. counterparts.

European VC trends: series A funding and top biotech companies

Together, the Constellr series A funding and Aerska financings reflect broader trends in European venture capital:

1. Capital flowing into capital-intensive deep tech and biotech sectors
2. Increased cross-border investment participation
3. Growing ecosystem support from public and private investors

Europe’s venture landscape continues to evolve, supported by specialized funds, corporate strategic investors, and increasing integration with global capital networks.

Why Constellr and top biotech companies’ series A funding deals matter

For investors and industry stakeholders, these transactions reinforce several key themes:

1. Innovation beyond conventional tech sectors: From orbit to RNA medicines, European startups are tackling complex, high-value markets.
2. Sophistication of European VC: Fundraising sizes and investor participation reflect maturity and confidence in scaling ambitious ventures.
3. Addressing global challenges: Both space data analytics and CNS therapeutics address pressing societal needs with commercial potential.

Constellr, Aerska, and the rise of series A funding in Europe

The Constellr A series funding and Aerska funding milestones set a positive tone for European VC activity in 2026. As capital continues to flow into transformative technologies, Europe’s startup ecosystem is poised to deliver breakthroughs that resonate globally.

For venture investors, these deals highlight where innovation capital is concentrating: at the intersection of science, data, and real-world impact. With supportive policy environments and growing access to growth capital, Europe is emerging as a vibrant complementary ecosystem to the U.S. and Asia in the global venture capital landscape.

Looking ahead, European venture capital activity is expected to remain strong, particularly in deep tech, space technology, biotech, and RNA therapeutics. Investors are increasingly focusing on high-growth startups addressing critical global challenges, from climate monitoring and industrial analytics to central nervous system therapies.

Strategic funding rounds like those of Constellr and Aerska demonstrate Europe’s competitiveness in science-driven innovation and highlight opportunities for cross-border investment, corporate partnerships, and specialized venture funds. As the European startup ecosystem matures, entrepreneurs and investors alike are benefiting from increased access to growth capital, market intelligence, and networks that support scalable, high-impact technology ventures.